Provided by Tiger Trade Technology Pte. Ltd.

DEFIANCE DAILY TARGET 2X LONG HIMS ETF

27.09
-6.0400-18.23%
Post-market: 27.07-0.0200-0.07%19:59 EDT
Volume:571.16K
Turnover:16.13M
Market Cap:53.36M
PE:- -
High:32.60
Open:32.16
Low:26.51
Close:33.13
52wk High:391.58
52wk Low:12.38
Shares:1.97M
Float Shares:1.97M
Volume Ratio:1.87
T/O Rate:29.00%
Dividend:1.98
Dividend Rate:7.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Exclusive - U.S. Federal Trade Commission is Suing Hims & Hers over Billing, Cancellation and Privacy Practices, FTC Spokesperson Says

THOMSON REUTERS
·
Jul 30

Hims & Hers Health (HIMS) Receives a Hold from Truist Financial

TIPRANKS
·
Jul 29

Is Today’s Dip a Buying Opportunity for Hims & Hers Health (HIMS) Stock?

TIPRANKS
·
Jul 25

Hims & Hers falls -10.3%

TIPRANKS
·
Jul 25

Truist Raises Price Target on Hims & Hers Health to $27 From $23, Keeps Hold Rating

MT Newswires Live
·
Jul 24

Hims & Hers Health Inc : Truist Securities Raises Target Price to $27 from $23

THOMSON REUTERS
·
Jul 24

Moderately bullish activity in Hims and Hers Health with shares up 3.39%

TIPRANKS
·
Jul 24

Hims & Hers Health is Maintained at Neutral by Citigroup

Dow Jones
·
Jul 24

FDA Advisers Back First Four of Seven Unapproved Peptides Under Review for Looser Rules

Reuters
·
Jul 24

Why Is Hims & Hers Health Stock Surging on Thursday?

Benzinga
·
Jul 24

Hims Gains After FDA Panel Votes to Place Popularly Used Peptide Bpc-157 on Compounding List

Reuters
·
Jul 24

Hims & Hers Health Shares up 10% After FDA Advisory Panel Votes to Place Bpc-157 Peptide on Allowed Pharmacy Compounding List

THOMSON REUTERS
·
Jul 24

Hims & Hers Shares up 2% After Telehealth Firm Urged FDA to Broaden Access to Some Peptides in Panel Meeting

THOMSON REUTERS
·
Jul 23

Peptides Could Soon Become Widely Available in the U.S. Here's What Happens Next.

Dow Jones
·
Jul 23

Hims & Hers Health Inc : Citigroup Raises Target Price to $35 from $28

THOMSON REUTERS
·
Jul 23

Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares Valued at $229,075.99

Reuters
·
Jul 21

Trump's FDA May Soon Back Peptides. Should You Buy In?

Dow Jones
·
Jul 18

Hims & Hers Accounting Chief Exits

Dow Jones
·
Jul 18

Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company

THOMSON REUTERS
·
Jul 18

Cboe data shows mixed options sentiment in Hims and Hers Health with shares down 9.35%

TIPRANKS
·
Jul 17